| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Operating activities: | ||||||||||
Net income (loss) | ||||||||||
-11,016 | -471 | -42,611 | -37,949 | 1,856 | -13,716 | -63,909 | -52,281 | -43,328 | -27,149 | -31,707 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||||
Depreciation of fixed assets and amortization of intangible assets | ||||||||||
19,576 | 13,165 | 13,833 | 12,919 | 11,475 | 10,035 | 5,747 | 5,648 | 4,314 | 4,071 | 4,146 |
Amortization of debt issuance costs | ||||||||||
1,707 | 1,590 | 1,248 | 479 | 481 | 487 | 459 | -239 | -85 | -149 | 314 |
Amortization of debt discount | ||||||||||
13,746 | 12,799 | 10,423 | 4,088 | 4,102 | 4,139 | 3,959 | 831 | 1,644 | 146 | 600 |
Loss on disposal and impairment of fixed assets | ||||||||||
-1,010 | -65 | -2,133 | -389 | -6 | -158 | -32 | -1 | -273 | -11 | -1,707 |
Gain (Loss) on Extinguishment of Debt | ||||||||||
0 | - | -3,732 | 0 | -52 | - | -3,398 | -1,062 | 0 | -184 | - |
Loss on disposal and impairment of fixed assets | ||||||||||
- | - | - | - | - | - | - | - | 3,019 | - | - |
Stock-based compensation | ||||||||||
33,650 | 31,725 | 31,601 | 31,248 | 33,368 | 24,822 | 11,513 | 4,776 | 2,493 | 23 | 524 |
Changes in contingent consideration | ||||||||||
16,672 | 0 | 0 | - | - | - | - | - | - | - | - |
Loss on investment | ||||||||||
-4,315 | -854 | 0 | 0 | - | - | - | - | - | - | - |
Changes in operating assets and liabilities: | ||||||||||
Restricted cash | ||||||||||
- | - | - | - | -1,509 | -124 | 110 | 224 | -14 | 98 | 34 |
Accounts receivable, net | ||||||||||
8,524 | 5,999 | 1,721 | 4,082 | 3,489 | 7,776 | 10,238 | 2,239 | 922 | -264 | -1,130 |
Inventories, net | ||||||||||
8,026 | 7,157 | 10,133 | -30,367 | 32,382 | 13,706 | 3,480 | 10,832 | -360 | -124 | -299 |
Prepaid expenses and other assets | ||||||||||
3,885 | 3,228 | -3,476 | 3,377 | 2,007 | 1,621 | 972 | 59 | 608 | -32 | -244 |
Accounts payable, accrued expenses and income taxes payable | ||||||||||
- | - | - | - | 8,966 | 15,349 | 9,622 | 1,386 | 2,549 | -1,118 | -4,438 |
Royalty interest obligation | ||||||||||
- | - | - | - | 276 | 970 | 434 | 1,076 | 1,815 | 675 | -185 |
Deferred revenue | ||||||||||
- | - | - | - | - | 6,713 | -472 | -16,778 | 1,065 | -2,328 | 3,793 |
Accounts payable | ||||||||||
-1,822 | -573 | 5,712 | -350 | - | - | - | - | - | - | - |
Accrued expenses and income taxes payable | ||||||||||
20,213 | 5,203 | 3,647 | 1,060 | - | - | - | - | - | - | - |
Other liabilities | ||||||||||
-6,726 | 897 | -3,555 | -1,339 | 4,360 | 2,526 | 1,047 | -106 | 27 | 1,782 | 3,027 |
Payment of contingent consideration to MyoScience, Inc. securityholders | ||||||||||
370 | 0 | 0 | - | - | - | - | - | - | - | - |
Net cash provided by operating activities | ||||||||||
70,520 | 48,870 | 17,785 | 33,453 | 28,021 | 26,564 | -43,838 | -70,130 | -31,000 | -24,880 | -20,838 |
Investing activities: | ||||||||||
Purchases of fixed assets | ||||||||||
10,159 | 14,514 | 19,266 | 24,709 | 40,295 | 22,984 | 12,172 | 18,257 | 6,167 | 6,770 | 5,509 |
Proceeds from sales of fixed assets | ||||||||||
- | - | - | - | - | - | - | 1 | 14 | 1 | - |
Purchases of investments | ||||||||||
318,484 | 363,255 | 502,752 | 192,815 | 189,082 | 164,303 | 114,299 | 54,047 | 52,619 | - | - |
Sales of investments | ||||||||||
319,468 | 405,188 | 321,713 | 171,627 | 217,240 | 80,286 | 85,564 | 53,120 | 22,649 | - | - |
Purchases of long-term investments | ||||||||||
- | - | - | - | - | - | - | 0 | - | - | - |
Payment of contingent consideration | ||||||||||
0 | 6,843 | 8,460 | 15,857 | 7,119 | 13,433 | 2,031 | 10,339 | 0 | - | - |
Equity investment | ||||||||||
1,622 | 0 | 15,000 | 0 | 0 | - | - | - | - | - | - |
Proceeds from follow-on public offering, net | ||||||||||
- | - | - | - | - | 110,452 | 0 | 62,855 | - | - | - |
Net cash (used in) provided by investing activities | ||||||||||
-128,488 | 20,576 | -223,765 | -61,754 | -19,256 | -120,434 | -42,938 | -29,522 | -36,123 | -6,769 | -5,509 |
Financing activities: | ||||||||||
Proceeds from exercises of stock options | ||||||||||
8,469 | 7,170 | 6,778 | 5,770 | 10,073 | 7,239 | 3,856 | 870 | 136 | 2 | 3 |
Proceeds from shares issued under employee stock purchase plan | ||||||||||
2,402 | 1,784 | 1,862 | 1,495 | 2,093 | 1,184 | 0 | 0 | - | - | - |
Proceeds from initial public offering, net | ||||||||||
- | - | - | - | - | - | - | - | 38,016 | - | - |
Proceeds from offering, net | ||||||||||
- | - | - | - | - | - | - | - | 49,006 | - | - |
Purchase of treasury stock | ||||||||||
- | - | - | - | - | - | - | - | - | 2 | - |
Proceeds from issuance of 2022 convertible senior notes | ||||||||||
0 | 0 | 345,000 | 0 | 0 | 0 | 120,000 | 0 | 0 | 7,500 | 10,625 |
Conversion premium on 2019 convertible senior notes | ||||||||||
233 | 0 | 0 | - | - | - | - | - | - | - | - |
Proceeds from secured promissory notes and credit facility | ||||||||||
- | - | - | - | - | - | - | - | - | 56,250 | 10,625 |
Repayment of 2019 convertible senior notes | ||||||||||
338 | - | 118,193 | 4 | 1,467 | - | 27,500 | 26,250 | 0 | 11,250 | - |
Payment of debt issuance and financing costs | ||||||||||
0 | 0 | 11,000 | 0 | 0 | - | 7,191 | 1,365 | 0 | 1,795 | 215 |
Conversion premium on 2019 convertible senior notes | ||||||||||
0 | 0 | 285 | 0 | 0 | - | - | - | - | - | - |
Payments to Acquire Businesses, Net of Cash Acquired | ||||||||||
117,691 | 0 | 0 | - | - | - | - | - | - | - | - |
Payment of contingent consideration to MyoScience, Inc securityholders | ||||||||||
6,630 | 0 | 0 | - | - | - | - | - | - | - | - |
Conversion of principal and equity component of convertible senior notes | ||||||||||
- | - | - | - | - | 0 | - | 27,500 | 0 | - | - |
Net cash (used in) provided by financing activities | ||||||||||
3,670 | 8,954 | 224,162 | 7,261 | 10,699 | 118,875 | 89,165 | 63,610 | 87,158 | 50,705 | 21,038 |
Net (decrease) increase in cash and cash equivalents | ||||||||||
-54,298 | 78,400 | 18,182 | -21,040 | 19,464 | 25,005 | 2,389 | -36,042 | 20,035 | 19,056 | -5,309 |
Supplemental cash flow information: | ||||||||||
Cash paid for interest | ||||||||||
8,199 | 8,205 | 6,896 | 3,852 | 4,224 | 5,193 | 3,500 | 4,229 | 4,739 | 2,371 | 1,714 |
Cash paid for income taxes, net of refunds | ||||||||||
863 | 128 | 129 | 247 | 195 | 34 | 0 | 0 | - | - | - |
Initial public offering costs paid in 2010 | ||||||||||
- | - | - | - | - | - | - | - | 907 | - | - |
Non-cash investing and financing activities: | ||||||||||
Issuance of common stock from conversion of 2019 convertible senior notes | ||||||||||
0 | 0 | 120,960 | 0 | 3,929 | - | - | - | - | - | - |
Equity component of convertible senior notes | ||||||||||
- | - | - | - | - | 0 | 24,936 | 0 | 0 | - | - |
Issuance of common stock from conversion of 2019 convertible senior notes | ||||||||||
0 | 0 | 126,328 | 0 | 0 | 0 | 0 | - | - | - | - |
Non-cash investing and financing activities: | ||||||||||
Net increase in contingent consideration liabilities | ||||||||||
28,470 | 0 | 0 | - | - | - | - | - | - | - | - |
Net decrease in accrued fixed assets | ||||||||||
125 | -98 | 2,189 | -789 | 1,393 | -1,095 | 622 | - | - | - | 2,254 |
Accrual for repurchase of intangibles | ||||||||||
- | - | - | - | - | - | - | - | - | - | 323 |
Value of warrants issued with debt | ||||||||||
- | - | - | - | - | - | - | 1,354 | 0 | 1,692 | 537 |
Value of warrants issued to landlord | ||||||||||
- | - | - | - | - | - | - | - | - | - | 204 |
Accrued financing cost | ||||||||||
- | - | - | - | - | - | - | - | - | 500 | - |
Conversion of notes to common stock | ||||||||||
- | - | - | - | - | - | - | - | 51,222 | - | - |
Conversion of preferred stock to common stock | ||||||||||
- | - | - | - | - | - | - | - | 6 | - | - |